Approved & *emerging
applications
Elmiron® is the first and only FDA-approved oral therapy for Interstitial Cystitis / Bladder Pain Syndrome — a condition disproportionately affecting women — with emerging evidence supporting its use across a range of urothelial conditions relevant to women's health.
Approved & *emerging applications for women's bladder health
Interstitial Cystitis / BPS
Primary indication. A chronic bladder condition, disproportionately affecting women, causing pelvic pain, urgency, and frequency with no identifiable infection.
*Bladder Pain Syndrome
Suprapubic pain related to bladder filling, associated with at least one urinary symptom — common among women presenting with unresolved pelvic pain.
*Radiation Cystitis
Bladder inflammation following pelvic radiotherapy, including for gynaecological cancers. PPS aids mucosal repair and symptom relief.
*Hemorrhagic Cystitis
Hematuria and bladder irritation from chemotherapy agents. Intravesical PPS may help restore the protective barrier in affected women.
*Overactive Bladder (adjunct)
Used adjunctively in women with OAB who have co-existing urothelial dysfunction.
*Recurrent UTI Prevention
GAG layer restoration may reduce bacterial adherence and help prevent recurrent lower urinary tract infections, which women experience far more frequently than men.
Use of Elmiron for conditions other than IC/BPS may be considered off-label in some markets. Prescribers evaluating women with these presentations should review current evidence and regional regulatory status. Full prescribing information available on request from Medical Affairs.